toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
  Record Links
Author Smyth, A.R.; Barbato, A.; Beydon, N.; Bisgaard, H.; de Boeck, K.; Brand, P.; Bush, A.; Fauroux, B.; de Jongste, J.; Korppi, M.; O'Callaghan, C.; Pijnenburg, M.; Ratjen, F.; Southern, K.; Spencer, D.; Thomson, A.; Vyas, H.; Warris, A.; Merkus, P.J. url  doi
  Title Respiratory medicines for children: current evidence, unlicensed use and research priorities Type Journal Article
  Year (down) 2010 Publication The European Respiratory Journal Abbreviated Journal Eur Respir J  
  Volume 35 Issue 2 Pages 247-265  
  Keywords Adrenal Cortex Hormones/pharmacology; Anti-Bacterial Agents/pharmacology; Biomedical Research/trends; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy/methods; Evidence-Based Medicine; Humans; Immunosuppressive Agents/pharmacology; Infant; Infant, Newborn; Neonatal Screening; Off-Label Use; Pediatrics/*methods; Practice Patterns, Physicians'; Pulmonary Medicine/*methods; Respiration Disorders/*drug therapy  
  Abstract This European Respiratory Society task force has reviewed the evidence for paediatric medicines in respiratory disease occurring in adults and children. We describe off-licence use, research priorities and ongoing studies. Off-licence and off-label prescribing in children is widespread and potentially harmful. Research areas in asthma include novel formulations and regimens, and individualised prescribing. In cystic fibrosis, future studies will focus on screened infants and robust outcome measures are needed. Other areas include new enzyme and antibiotic formulations and the basic defect. Research into pneumonia should include evaluation of new antibacterials and regimens, rapid diagnostic tests and, in pleural infection, antibiotic penetration, fibrinolytics and surveillance. In uncommon conditions, such as primary ciliary dyskinesia, congenital pulmonary abnormalities or neuromuscular disorders, drugs indicated for other conditions (e.g. dornase alfa) are commonly used and trials are needed. In neuromuscular disorders, the beta-agonists may enhance muscle strength and are in need of evaluation. Studies of antibiotic prophylaxis, immunoglobulin and antifungal drugs are needed in immune deficiency. We hope that this summary of the evidence for respiratory medicines in children, highlighting gaps and research priorities, will be useful for the pharmaceutical industry, the paediatric committee of the European Medicines Agency, academic investigators and the lay public.  
  Address University of Nottingham Division of Child Health, Queens Medical Centre, Nottingham, NG7 2UH, UK.  
  Corporate Author Thesis  
  Impact Factor 07,636 First Author Smyth, A.R. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Merkus, P.J.  
  ISSN 0903-1936 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:19840958 Approved no  
  Call Number Serial 143  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: